Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to $81000.0.

  • Silence Therapeutics' Depreciation & Amortization (CF) fell 4173.71% to $81000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $311000.0, marking a year-over-year decrease of 4423.36%. This contributed to the annual value of $336000.0 for FY2024, which is 4140.34% down from last year.
  • Silence Therapeutics' Depreciation & Amortization (CF) amounted to $81000.0 in Q3 2025, which was down 4173.71% from $81000.0 recorded in Q2 2025.
  • Silence Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $169607.3 during Q1 2021, with a 5-year trough of $73000.0 in Q1 2025.
  • Over the past 5 years, Silence Therapeutics' median Depreciation & Amortization (CF) value was $140805.5 (recorded in 2024), while the average stood at $129528.3.
  • In the last 5 years, Silence Therapeutics' Depreciation & Amortization (CF) crashed by 6390.29% in 2021 and then skyrocketed by 9169.79% in 2022.
  • Over the past 5 years, Silence Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $86272.7 in 2021, then soared by 91.7% to $165382.9 in 2022, then dropped by 15.95% to $139009.0 in 2023, then crashed by 45.33% to $76000.0 in 2024, then increased by 6.58% to $81000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $81000.0 for Q3 2025, versus $81000.0 for Q2 2025 and $73000.0 for Q1 2025.